Literature DB >> 20026612

In vitro pharmacodynamic models to determine the effect of antibacterial drugs.

Julia Gloede1, Christian Scheerans, Hartmut Derendorf, Charlotte Kloft.   

Abstract

In vitro pharmacodynamic (PD) models are used to obtain useful quantitative information on the effect of either single drugs or drug combinations against bacteria. This review provides an overview of in vitro PD models and their experimental implementation. Models are categorized on the basis of whether the drug concentration remains constant or changes and whether there is a loss of bacteria from the system. Further subdifferentiation is based on whether bacterial loss involves dilution of the medium or is associated with dialysis or diffusion. For comprehension of the underlying principles, experimental settings are simplified and schematically illustrated, including the simulations of various in vivo routes of administration. The different model types are categorized and their (dis)advantages discussed. The application of in vitro models to special organs, infections and pathogens is comprehensively presented. Finally, the relevance and perspectives of in vitro investigations in drug discovery and clinical research are elucidated and discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026612     DOI: 10.1093/jac/dkp434

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  35 in total

Review 1.  [Pharmacokinetics and pharmacodynamics of antibiotic therapy].

Authors:  S Beck; S G Wicha; C Kloft; M G Kees
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

Review 2.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

3.  Polymyxin resistance in Klebsiella pneumoniae: multifaceted mechanisms utilized in the presence and absence of the plasmid-encoded phosphoethanolamine transferase gene mcr-1.

Authors:  Sue C Nang; Mei-Ling Han; Heidi H Yu; Jiping Wang; Von Vergel L Torres; Chongshan Dai; Tony Velkov; Marina Harper; Jian Li
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

4.  Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

Authors:  Yuan-Cheng Chen; Wang Liang; Jia-Li Hu; Gao-Li He; Xiao-Jie Wu; Xiao-Fang Liu; Jing Zhang; Xue-Qian Hu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-30       Impact factor: 2.745

6.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

Review 7.  The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.

Authors:  Elisabeth Hodille; Warren Rose; Binh An Diep; Sylvain Goutelle; Gerard Lina; Oana Dumitrescu
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

8.  New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.

Authors:  Janus A J Haagensen; Davide Verotta; Liusheng Huang; Alfred Spormann; Katherine Yang
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

9.  Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.

Authors:  Wang Liang; Yuan-cheng Chen; Yu-ran Cao; Xiao-fang Liu; Jun Huang; Jia-li Hu; Miao Zhao; Qing-lan Guo; Shu-jing Zhang; Xiao-jie Wu; De-mei Zhu; Ying-yuan Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

10.  Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry.

Authors:  Gabriel J LaBonia; Sarah Y Lockwood; Andrew A Heller; Dana M Spence; Amanda B Hummon
Journal:  Proteomics       Date:  2016-06       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.